



Tobira Therapeutics  
Investor Relations Department  
701 Gateway Blvd  
Suite 300  
South San Francisco, CA 94080  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: TBRA

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 42.09                      |
| Trade Time:   | 4:00 PM ET<br>Oct 31, 2016 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 3.76 - 42.33               |
| Volume        | N/A                        |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA.

... [\(more\)](#)

## Stock Performance

Chart is not available for this symbol

## Press Releases [\[ View all \]](#)

*Oct 20, 2016*

[Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting](#)

*Oct 19, 2016*

[Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira](#)

*Oct 3, 2016*

[Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting](#)

*Sep 20, 2016*

[Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH](#)

*Sep 12, 2016*

[Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 3, 2016*

[Annual Report \(10-K\)](#)

*Apr 28, 2016*

[Proxy Statement \(DEF 14A\)](#)

*Aug 9, 2016*

[Quarterly Report \(10-Q\)](#)

*May 9, 2016*

[Quarterly Report \(10-Q\)](#)

*Nov 10, 2015*

[Quarterly Report \(10-Q\)](#)